Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that its proprietary NIMBUS® antimicrobial technology has been approved for manufacture, marketing and sale in India. Viridis BioPharma, an India-based manufacturer and marketer of medical devices, received approval by the Food and Drug Administration (FDA) of India to manufacture and market gauze wound dressings that incorporate NIMBUS® antimicrobial technology.
"The approval of our proprietary NIMBUS antimicrobial wound care technology by the India FDA marks an important milestone for both Quick-Med and Viridis," said J. Ladd Greeno, Quick-Med's CEO. "India's large wound care market represents a significant opportunity for Viridis to drive sales with our unique, value-added NIMBUS antimicrobial feature."
Dr. Dilip Mehta, CEO of Viridis BioPharma, commented, "We see this approval to manufacture and market NIMBUS technology based antimicrobial gauze dressings as a paradigm shift in the burn and wound care management. There will be an unparalleled protection afforded against infections to a major percentage of the affected population."
Viridis BioPharma plans to have its first NIMBUS products on the market in the second quarter of 2011.
Quick-Med expects NIMBUS to become an important technology in the $14 billion global wound care market, as wound care companies and health care professionals look for more effective and efficient ways to prevent infections and avoid cross-contamination. By incorporating a non-leaching antimicrobial, bandages with NIMBUS technology can diminish the opportunities for infection and cross-contamination.
Quick-Med Technologies, Inc.